Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age

Rosendahl, Mikkel; Andersen, Claus Yding; Freiesleben, Nina la Cour; Juul, Anders; Løssl, Kristine; Andersen, Anders Nyboe

doi:10.1016/j.fertnstert.2009.02.043

Cited by 130 publications

(120 citation statements)

References 29 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…The follow-up period of 6 years after the start of treatment does not seem to be too short, in view of the fact that testicular recovery occurs in the initial years after HSCT and that the sharpest decline in ovarian reserve takes place immediately after treatment. 19,20 Seven children were born to the overall group, all at term and healthy. None of the female participants who became pregnant or male patients who fathered a child had been treated with TBI before HSCT.…”

Section: Discussionmentioning

confidence: 99%

Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence

Borgmann‐Staudt

Rendtorff

Reinmuth

et al. 2011

Bone Marrow Transplant

158

123

View full text Add to dashboard Cite

Infertility is a major late effect in patients receiving haematopoietic stem cell transplantation (HSCT). The aim of this study was to determine the proportion of patients having fertility impairment after allogeneic HSCT in childhood/adolescence and to identify the potential risk factors. Treatment and fertility data of paediatric patients with malignant and non-malignant diseases treated with allogeneic HSCT between 2000 and 2005 were collected from seven European centres. Data were obtained for 138 female and 206 male patients after a median follow-up of 6 years (range 3-12). The patients' median age was 13 years (range 4-28) at the time of years at the time of the enquiry. Seven children were born to the overall group, all at term and healthy. Fertility impairment was suspected in 69% males and 83% females. Start of treatment at age X13 years was a risk factor in females (odds ratio (OR) 4.7; 95% confidence interval (CI), 1.5 to 14.9), whereas pre-pubertal therapy was a risk factor in males (OR 0.4; 95% CI, 0.2 to 0.8). The major treatment-related risk factors were BU in females (OR 47.4; 95% CI, 5.4 to 418.1) and TBI in males (OR 7.7; 95% CI, 2.3 to 25.4). In light of the significant proportion of HSCT patients reviewed with impaired fertility, fertility conservation procedures should be considered for all patients undergoing HSCT, particularly those receiving TBI or BU-based preparative regimens.

show abstract

Section: Discussionmentioning

confidence: 99%

Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence

Borgmann‐Staudt

Rendtorff

Reinmuth

et al. 2011

Bone Marrow Transplant

158

123

View full text Add to dashboard Cite

show abstract

“…This analysis clearly demonstrates the toxicity of alkylating agent-based therapy (Decanter et al 2010). Rosendahl et al (2010) evaluated AMH and hormonal markers in 17 patients with a hematological malignancy or breast cancer before, during, and after chemotherapy. They showed that AMH and inhibin B levels immediately declined after chemotherapy administration, indicating direct chemotherapy-induced damage to the granulosa cells of the growing follicles.…”

Section: Amh and Chemo-induced Gonadal Damage In Cancer Patientsmentioning

confidence: 93%

“…They showed that AMH and inhibin B levels immediately declined after chemotherapy administration, indicating direct chemotherapy-induced damage to the granulosa cells of the growing follicles. Furthermore, they showed that high pretreatment AMH levels were predictive of higher AMH levels during recovery of ovarian function after chemotherapy (Rosendahl et al 2010). Brougham et al (2012) prospectively evaluated AMH levels in children as a marker of ovarian reserve during cancer treatment.…”

Section: Amh and Chemo-induced Gonadal Damage In Cancer Patientsmentioning

confidence: 99%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

“…In this way, it may be a more sensitive predictor of ovarian reserve than other markers, such as AFC and inhibin-B, which detect more mature primordial follicles. Some studies exhibit interesting results Anderson & Cameron (2011);Domingues et al (2010); Knauff et al (2009);Rosendahl et al (2010);Yu et al (2010). In the study of Partridge et al (2010), AFC and AMH seem to be the best markers of ovarian reserve.…”

Section: Assessing Post-chemotherapy Ovarian Functionmentioning

confidence: 97%

Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity

Berlière¹,

Duhoux²,

Galant³

et al. 2011

Amenorrhea

View full text Add to dashboard Cite

Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age

Cited by 130 publications

References 29 publications

Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence

Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity

Contact Info

Product

Resources

About